- Home
- QURE vs PHAR Comparison
QURE vs PHAR Comparison
Compare QURE & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- PHAR
- Stock Information
- Founded
- QURE 1998
- PHAR 1988
- Country
- QURE Netherlands
- PHAR Netherlands
- Employees
- QURE N/A
- PHAR N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- QURE Health Care
- PHAR Health Care
- Exchange
- QURE Nasdaq
- PHAR Nasdaq
- Market Cap
- QURE 866.3M
- PHAR 951.7M
- IPO Year
- QURE 2007
- PHAR N/A
- Fundamental
- Price
- QURE $14.16
- PHAR $14.60
- Analyst Decision
- QURE Strong Buy
- PHAR Strong Buy
- Analyst Count
- QURE 11
- PHAR 3
- Target Price
- QURE $39.91
- PHAR $30.00
- AVG Volume (30 Days)
- QURE 1.1M
- PHAR 12.7K
- Earning Date
- QURE 11-04-2025
- PHAR 10-23-2025
- Dividend Yield
- QURE N/A
- PHAR N/A
- EPS Growth
- QURE N/A
- PHAR N/A
- EPS
- QURE N/A
- PHAR N/A
- Revenue
- QURE $14,337,000.00
- PHAR $339,836,000.00
- Revenue This Year
- QURE N/A
- PHAR $16.63
- Revenue Next Year
- QURE $288.08
- PHAR $6.77
- P/E Ratio
- QURE N/A
- PHAR N/A
- Revenue Growth
- QURE N/A
- PHAR 22.44
- 52 Week Low
- QURE $4.45
- PHAR $7.31
- 52 Week High
- QURE $19.18
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- QURE 34.28
- PHAR 56.71
- Support Level
- QURE $17.03
- PHAR $13.63
- Resistance Level
- QURE $17.76
- PHAR $15.27
- Average True Range (ATR)
- QURE 0.95
- PHAR 0.96
- MACD
- QURE -0.39
- PHAR -0.13
- Stochastic Oscillator
- QURE 3.13
- PHAR 51.83
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.